Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Indapta Therapeutics.

    Client Virtual Booth

    INDAPTA THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Indapta Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Francisco, CA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://indapta.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin’s Lymphoma and Myeloma

    Details:

    IDP-023 is an allogeneic G-NK cell therapy, which is being evaluated for the treatment of patients with non-Hodgkin’s lymphoma and multiple myeloma.


    Lead Product(s): IDP-023,Cyclophosphamide,Fludarabine Phosphate

    Therapeutic Area: Oncology Product Name: IDP-023

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 29, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Indapta Therapeutics Announces First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer

    Details:

    IDP-023 is a natural killer (NK) cell therapy which is currently being investigated in phase 1/2 clinical studies for the treatment of multiple myeloma and Non-Hodgkin’s lymphoma.


    Lead Product(s): IDP-023,Cyclophosphamide,Fludarabine Phosphate

    Therapeutic Area: Oncology Product Name: IDP-023

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 11, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer

    Details:

    The financing will be used for the first-in-human phase 1 trial of DP-023, an Allogeneic Natural Killer (NK) Cell Therapy in patients with multiple myeloma and lymphoma.


    Lead Product(s): IDP-023,Antibody

    Therapeutic Area: Oncology Product Name: IDP-023

    Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Leaps by Bayer

    Deal Size: $60.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing May 17, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance ...

    Details:

    The company will use the proceeds of the financing to grow the team and continue to advance its universal, allogeneic NK cell platform toward an Investigational New Drug Application (IND) and clinical trials.


    Lead Product(s): G-NK cells

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: RA Capital Management

    Deal Size: $50.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing February 10, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search